Drug Discovery
PRI focuses on in vitro and in vivo models of disease across multiple therapeutic areas:
Hematology/Oncology
- Angiogenesis modulation
- Thrombosis (Coagulation/platelet)
- Cancer biology
Cardiovascular (Dyslipidemia)
- LDL-C lowering targets
- HDL-C raising targets
- Preclinical models of dyslipidemia
- Targeted delivery
Vascular Diseases
- Peripheral Artery Disease
- Cell therapy
- Pharmacotherapy
- Combination therapy
- Cardiovascular Diseases
- Acute Coronary Syndrome
- Cerebrovascular Diseases
- Stroke
Ophthalmology
- Downregulation of pathological angiogenesis (retina and choroidal neovascularization) in diabetic retinopathy and macular degeneration
- Ocular delivery of angiogenesis modulators
Neurology
- Pain modulation in cancer, inflammatory, and other disorders
- Nano-targeted delivery across the blood-brain barrier
Inflammation
- Development of novel anti-inflammatory targets including NFκB and other pathways in various acute and chronic inflammatory disorders